Georgios N. Pongas

Georgios N. Pongas

Hematology Oncology | Hematology

1475 Northwest 12th Avenue
Miami, FL 33136

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Journal: Blood cancer journal

Published: December 12, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances

Published: September 24, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances

Published: September 24, 2025

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Journal: Blood advances

Published: September 24, 2025

Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.

Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.

Journal: Blood advances

Published: September 17, 2025

Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.

Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.

Journal: Blood advances

Published: September 17, 2025

Peripheral blood involvement in extra-nodal marginal zone lymphoma.

Peripheral blood involvement in extra-nodal marginal zone lymphoma.

Journal: British journal of haematology

Published: September 08, 2025

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis.

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis.

Journal: Blood cancer journal

Published: January 31, 2025

High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter syndrome.

High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter syndrome.

Journal: Blood advances

Published: January 14, 2025

Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial.

Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: October 10, 2024

Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies.

Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies.

Journal: Cancers

Published: July 15, 2024

Successful treatment of a CLL associated IgM hyper-viscosity syndrome: A rare case.

Successful treatment of a CLL associated IgM hyper-viscosity syndrome: A rare case.

Journal: Leukemia research reports

Published: April 23, 2024

Showing 1-12 of 30

Last Updated: 09/26/2026